Every Cure
Matt Goddeeris currently serves as the Vice President of Discovery at Every Cure since February 2025. Prior to this role, Matt held various leadership positions at Cellarity from July 2021 to February 2025, including Vice President of Discovery Science and Head of Exploratory Biology. From July 2018 to July 2021, Matt was the Vice President of Research at Eloxx Pharmaceuticals, leading non-clinical and pre-clinical research efforts. At Mitobridge, Inc., from July 2014 to July 2018, Matt advanced from Principal Scientist to Executive Director of Research, overseeing programs from discovery to clinical trials. Earlier experience includes positions at the University of Iowa, focusing on translational biology and disease modeling. Matt obtained a PhD in Cell and Developmental Biology from Duke University and a BS in Biochemistry/Biotechnology from Michigan State University.
This person is not in any teams
This person is not in any offices
Every Cure
1 followers
Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.